Yanping Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanping Yin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anthony R. Mato
Memorial Sloan Kettering Cancer Center, New York, New York
30 shared publications - Haifeng Xu
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
30 shared publications - Jennifer R. Brown
Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
30 shared publications - Sigrid S. Skånland
Department of Cancer Immunology, Institute for Cancer Research Oslo University Hospital Oslo Norway
30 shared publications - Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
30 shared publications - Abdul K. Hilli
Department of Medicine, Diakonhjemmet Hospital, Oslo, Norway
19 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 4. Compound library.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 4. Compound library.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Purpose:The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are necessary. In this study, we used the phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as a model to (i) understand the impact of targeted treatment on cell signaling and immunophenotypes in responders and nonresponders, (ii) identify molecular features that predict individual treatment responses, and (iii) suggest alternative treatment options for the nonresponders.Experimental Design:We performed functional phenotyping of CLL cells from patients enrolled in two clinical trials with umbralisib, administered either as a monotherapy (NCT02742090, n = 55) or in combination with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (NCT04624633, n = 12).Results:We found that umbralisib monotherapy led to significant changes in (phospho)protein levels, including AKT (pS473), in responders but not in nonresponders. Furthermore, the proportion of cytotoxic natural killer (NK) cells increased at the end of the study but only in responders, suggesting a role in the antitumor response. To identify molecular predictors of response, we used the baseline levels of 30 (phospho)proteins in the monotherapy cohort as input features for a machine learning model, which achieved significant prediction accuracy in cross-validation and maintained its predictive power in the combination cohort. Drug sensitivity profiling of the CLL cells at baseline suggested that PI3K + Bcl-2 inhibitors are effective in umbralisib nonresponders.Conclusions:Functional phenotyping reveals differential cellular responses to umbralisib treatment in responders and nonresponders; predicts treatment response of individual patients with CLL; and suggests alternative treatment options for the nonresponders.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Purpose:The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are necessary. In this study, we used the phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as a model to (i) understand the impact of targeted treatment on cell signaling and immunophenotypes in responders and nonresponders, (ii) identify molecular features that predict individual treatment responses, and (iii) suggest alternative treatment options for the nonresponders.Experimental Design:We performed functional phenotyping of CLL cells from patients enrolled in two clinical trials with umbralisib, administered either as a monotherapy (NCT02742090, n = 55) or in combination with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (NCT04624633, n = 12).Results:We found that umbralisib monotherapy led to significant changes in (phospho)protein levels, including AKT (pS473), in responders but not in nonresponders. Furthermore, the proportion of cytotoxic natural killer (NK) cells increased at the end of the study but only in responders, suggesting a role in the antitumor response. To identify molecular predictors of response, we used the baseline levels of 30 (phospho)proteins in the monotherapy cohort as input features for a machine learning model, which achieved significant prediction accuracy in cross-validation and maintained its predictive power in the combination cohort. Drug sensitivity profiling of the CLL cells at baseline suggested that PI3K + Bcl-2 inhibitors are effective in umbralisib nonresponders.Conclusions:Functional phenotyping reveals differential cellular responses to umbralisib treatment in responders and nonresponders; predicts treatment response of individual patients with CLL; and suggests alternative treatment options for the nonresponders.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 8. k-means clustering.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 8. k-means clustering.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 5. Drug combinations.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 5. Drug combinations.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 7. The eight most common adverse events in cohort 1.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 7. The eight most common adverse events in cohort 1.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 2. Patient samples of NCT02742090 (cohort 1).
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 2. Patient samples of NCT02742090 (cohort 1).
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 1. Patient characteristics for biobanked CLL samples.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 1. Patient characteristics for biobanked CLL samples.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 3. Patient samples of NCT04624633 (cohort 2).
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 3. Patient samples of NCT04624633 (cohort 2).
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 6. The performance of using (phospho)proteins to predict IGHV mutational status.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Supplementary Table 6. The performance of using (phospho)proteins to predict IGHV mutational status.